[Influenza in children: what should be considered in prevention and treatment?].
Panknin
Hardy-Thorsten
HT
ht.panknin@tiscali.de
Trautmann
Matthias
M
D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D005260:Female; D005858:Germany; D006801:Humans; D007223:Infant; D017757:Infectious Disease Transmission, Professional-to-Patient / Q000517:prevention & control; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects; D007251:Influenza, Human / Q000453:epidemiology / Q000451:nursing* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D009439:Neuraminidase / Q000037:antagonists & inhibitors; D053139:Oseltamivir / Q000009:adverse effects / Q000627:therapeutic use; D012621:Seasons; D053243:Zanamivir / Q000009:adverse effects / Q000627:therapeutic use
D000998:Antiviral Agents; D007252:Influenza Vaccines; D053139:Oseltamivir; D009439:Neuraminidase; D053243:Zanamivir